检索结果 - Judith‐Anne W. Chapman

  • Showing 1 - 4 results of 4
Refine Results
  1. 1
    Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial

    Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial 由 Vivien Bramwell, Alan B. Tuck, Judith‐Anne W. Chapman, Pieter H. Anborgh, Carl O. Postenka, Waleed Al‐Katib, Lois E. Shepherd, Lei Han, Carolyn F. Wilson, Kathleen I. Pritchard, Michaël Pollak, Ann F. Chambers

    出版 2014
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  2. 2
    Cyclophosphamide, Epirubicin, and Fluorouracil Versus Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel Versus Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Node-Positive or High-Risk Node-Negative Breast Cancer

    Cyclophosphamide, Epirubicin, and Fluorouracil Versus Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel Versus Doxorubicin and Cyclophosphamide Followed by Paclitax... 由 Margot J. Burnell, Mark N. Levine, Judith‐Anne W. Chapman, Vivien Bramwell, Karen A. Gelmon, Barbara Walley, Ted Vandenberg, Haji Chalchal, Kathy S. Albain, Edith A. Perez, Hope S. Rugo, Kathleen I. Pritchard, Patti O’Brien, Lois E. Shepherd

    出版 2009
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    Randomized Trial of Tamoxifen Versus Combined Tamoxifen and Octreotide LAR Therapy in the Adjuvant Treatment of Early-Stage Breast Cancer in Postmenopausal Women: NCIC CTG MA.14

    Randomized Trial of Tamoxifen Versus Combined Tamoxifen and Octreotide LAR Therapy in the Adjuvant Treatment of Early-Stage Breast Cancer in Postmenopausal Women: NCIC CTG MA.14 由 Kathleen I. Pritchard, Lois E. Shepherd, Judith‐Anne W. Chapman, B. Norris, Jacques Cantin, Paul E. Goss, Susan Dent, David Walde, Ted Vandenberg, B. Findlay, Susan E. O’Reilly, Carolyn F. Wilson, Lei Han, Ettie Piura, Timothy J. Whelan, Michaël Pollak

    出版 2011
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  4. 4
    Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31

    Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31 由 Karen A. Gelmon, Frances Boyle, Bella Kaufman, David G. Huntsman, Alexey Manikhas, Angelo Di Leo, Miguel Martín, Lee S. Schwartzberg, Julie Lemieux, Samuel Aparício, Lois E. Shepherd, Susan Dent, Susan Ellard, Katia Tonkin, Kathleen I. Pritchard, Timothy J. Whelan, Dora Nomikos, Arnd Nusch, Robert E. Coleman, Hirofumi Mukai, Sergei Tjulandin, Р. Ш. Хасанов, Shulamith Rizel, Anne P. Connor, Sergio Santillana, Judith‐Anne W. Chapman, Wendy R. Parulekar

    出版 2015
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: